<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188863</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-102-DM</org_study_id>
    <secondary_id>LX4211.102</secondary_id>
    <nct_id>NCT01188863</nct_id>
  </id_info>
  <brief_title>Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Three-Way Crossover Study of Two Oral Formulations of LX4211 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is intended to compare the effects of both a solid (tablet) and liquid oral
      dosage form of LX4211 in subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>Pharmacokinetics samples collected on day of dosing and 24 and 48 hours post-dose (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which maximum observed plasma concentration occurs</measure>
    <time_frame>Pharmacokinetics samples collected on day of dosing and 24 and 48 hours post-dose (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of the drug in plasma</measure>
    <time_frame>Pharmacokinetics samples collected on day of dosing and 24 and 48 hours post-dose (Follow-up).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>Samples collected on initial visit; Day -15 and Day -5 (Washout); numerous timepoints on Day -1 (Washout) and day of dosing; 24 hours post-dose (Follow-up); and upon discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>Samples collected on Day -1 (Washout), day of dosing, and 24 and 48 hours post-dose (Follow-up).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>Samples collected on initial visit; Day -15 and Day -5 (Washout); numerous timepoints on Day -1 (Washout) and day of dosing; 24 hours post-dose (Follow-up); and upon discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY</measure>
    <time_frame>Samples collected on initial visit; Day -15 and Day -5 (Washout); numerous timepoints on Day -1 (Washout) and day of dosing; 24 hours post-dose (Follow-up); and upon discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like Peptide 1</measure>
    <time_frame>Samples collected on initial visit; Day -15 and Day -5 (Washout); numerous timepoints on Day -1 (Washout) and day of dosing; 24 hours post-dose (Follow-up); and upon discharge.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Solid Oral Dose - 150 mg tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid Oral Dose - 50 mg tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid Oral Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg LX4211 (150 mg tablets)</intervention_name>
    <description>Single oral dose of two 150 mg tablets LX4211</description>
    <arm_group_label>Solid Oral Dose - 150 mg tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg LX4211 (50 mg tablets)</intervention_name>
    <description>Single oral dose of six 50 mg tablets LX4211</description>
    <arm_group_label>Solid Oral Dose - 50 mg tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg LX4211 (liquid)</intervention_name>
    <description>Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)</description>
    <arm_group_label>Liquid Oral Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 to 65 years of age

          -  Males and females of non-childbearing potential

          -  Diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening

          -  Fasting plasma glucose ≤240 mg/dL

          -  Body mass index &lt;42 kg/sq m

          -  HbA1c of 7-11%

          -  C-peptide of ≥1.0 ng/mL

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketonic
             syndrome, incontinence, or nocturia

          -  Current use of any blood glucose-lowering agent other than metformin

          -  Exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening

          -  History of HIV, Hepatitis B, or Hepatitis C

          -  Surgery within 6 months of screening

          -  Donation or loss of &gt;400 mL of blood or blood product within 8 weeks prior to start of
             study

          -  Use of proteins or antibodies within 12 weeks prior to screening. (Flu shots are
             allowed.)

          -  Exposure to any investigational agent or participation in an investigational trial
             within 30 days of the start of the study

          -  History of drug or alcohol abuse within 12 months prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel P. Freiman, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>March 29, 2011</last_update_submitted>
  <last_update_submitted_qc>March 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joel P. Freiman, MD, MPH</name_title>
    <organization>Lexicon Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

